← Back
Data updated: Mar 10, 2026
BIOCON PHARMA
CardiovascularInfectious DiseaseOncology
BIOCON PHARMA is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Oncology. Key products include DAPTOMYCIN.
2006
Since
23
Drugs
-
Trials
332
Approved (2yr)
Recent Activity
LIRAGLUTIDE 2026-02-24
MICAFUNGIN SODIUM 2026-02-24
LIRAGLUTIDE 2026-02-24
RIVAROXABAN 2026-02-20
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
TOFACITINIB CITRATE 2026-02-18
Labeling
PRAVASTATIN SODIUM 2026-02-06
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 25%
3 drugs
Infectious Disease 25%
3 drugs
Oncology 25%
3 drugs
Metabolic 17%
2 drugs
Neurology 8%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Cardiovascular, Infectious Disease, Neurology
AZURITY specialty
Cardiovascular, Oncology, Neurology, Metabolic, Infectious Disease
GE HEALTHCARE specialty
Infectious Disease, Neurology, Cardiovascular, Oncology
Active (19)
RIVAROXABAN LIRAGLUTIDE SACUBITRIL AND VALSARTAN PEMETREXED DISODIUM LENALIDOMIDE POSACONAZOLE MICAFUNGIN SODIUM TERIFLUNOMIDE DASATINIB ROSUVASTATIN CALCIUM DAPTOMYCIN MYCOPHENOLATE SODIUM ATORVASTATIN CALCIUM TACROLIMUS OXCARBAZEPINE SIMVASTATIN PRAVASTATIN SODIUM NOREPINEPHRINE BITARTRATE NITROFURANTOIN
Discontinued (3)
Company Info
- First Approval
- 2006-12-20
- Latest
- 2026-02-24
- Applications
- 28
FDA Sponsor Names
BIOCON PHARMABIOCON PHARMA LTD